WO2000038785A2 - Methods for treating certain diseases using naaladase inhibitors - Google Patents
Methods for treating certain diseases using naaladase inhibitors Download PDFInfo
- Publication number
- WO2000038785A2 WO2000038785A2 PCT/US1999/031039 US9931039W WO0038785A2 WO 2000038785 A2 WO2000038785 A2 WO 2000038785A2 US 9931039 W US9931039 W US 9931039W WO 0038785 A2 WO0038785 A2 WO 0038785A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- tgf
- condition
- mammal
- pentanedioic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- FIG. 3 is a bar graph showing the reversal of the neuroprotective effect of compound 3 by TGF- ⁇ neutralizing antibodies.
- FIG. 4 is a bar graph showing of the non-reversal of the neuroprotective effect of compound 3 by FGF neutralizing antibodies.
- Compound 1 refers to pure and impure forms of 2- (2-sulfanylethyl) pentanedioic acid, or the compound prepared by Example 23.
- Compound 2 refers to 2- [ [ (2 , 3, 4 , 5, 6- pentafluorobenzyl) hydroxyphosphmyl] methyl] -pentanedioic acid.
- Carboxylic acid isosteres include without limitation direct derivatives such as hydroxamic acids, acyl-cyanamides and acylsulfonamides ; planar acidic heterocycles such as tetrazoles, mercaptoazoles, sulfmylazoles, sulfonylazoles , isoxazoles, isothiazoles, hydroxythiadiazole and hydroxychromes; and nonplanar sulfur- or phosphorus-derived acidic functions such as phosphinates, phosphonates, phosphonamides, sulphonates, sulphonamides, and acylsulphonamides .
- direct derivatives such as hydroxamic acids, acyl-cyanamides and acylsulfonamides
- planar acidic heterocycles such as tetrazoles, mercaptoazoles, sulfmylazoles, sulfonylazoles , isoxazoles, isothi
- the present invention provides methods for treating cell-growth related disorders in an animal or mammal, the method comprising administering an effective amount of a NAALADase inhibitor to said animal or mammal.
- the treated cells are selected from the group consisting of kidney cells, hematopoietic cells, lymphocytes, epithelial cells, and endothelial cells .
- the present invention provides methods for treating neurodegenerative disorders in an animal or mammal, the method comprising administering an effective amount of a NAALADase inhibitor to said animal or mammal.
- the neurodegenerative disorder is selected from the group consisting of neural tissue damage resulting from ischemia reperfusion injury, myelination, and neuroregeneration.
- the NAALADase inhibitors may also be administered in the form of sterile injectable preparations, for example, as sterile injectable aqueous or oleaginous suspensions. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparations may also be sterile injectable solutions or suspensions in non-toxic parenterally- acceptable diluents or solvents, for example, as solutions in 1, 3-butanediol .
- acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils are conventionally employed as solvents or suspending mediums.
- MPO Assay Procedure Myeloperoxidase (MPO) isolated from human polymorphonuclear leukocytes (Calbiochem, Cat. No 475911) is used. Test compound and/or vehicle is pre-incubated with 0.02 ⁇ g enzyme and 0.0085% hexadecyltrimethylammonium bromide in lOOmM potassium phosphate buffer pH 7.4 for 30 minutes at 25°C. The reaction is then initiated by addition of ImM guaiacol as substrate plus 0.15% H202 and run for another 5 minutes. The formation of tetraguaiacol is measured by the increase in absorbance at 450nm. Compounds are screened at 10 ⁇ M. Reference Data - MPO Assay
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002354052A CA2354052A1 (en) | 1998-12-31 | 1999-12-29 | Methods for treating certain diseases using naaladase inhibitors |
AT99967675T ATE248592T1 (en) | 1998-12-31 | 1999-12-29 | USE OF NAALADASE INHIBITORS TO PRODUCE A MEDICATION FOR THE TREATMENT OF CERTAIN DISEASES |
EP99967675A EP1140048B1 (en) | 1998-12-31 | 1999-12-29 | Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases |
DE69911057T DE69911057D1 (en) | 1998-12-31 | 1999-12-29 | USE OF NAALADASE INHIBITORS FOR PRODUCING A MEDICINE FOR TREATING CERTAIN DISEASES |
AU23921/00A AU2392100A (en) | 1998-12-31 | 1999-12-29 | Methods for treating certain diseases using naaladase inhibitors |
JP2000590733A JP2002533421A (en) | 1998-12-31 | 1999-12-29 | Disease treatment using NAALADase inhibitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22429198A | 1998-12-31 | 1998-12-31 | |
US09/224,291 | 1998-12-31 | ||
US09/425,197 | 1999-10-22 | ||
US09/425,197 US6444657B1 (en) | 1998-12-31 | 1999-10-22 | Methods for treating certain diseases using naaladase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000038785A2 true WO2000038785A2 (en) | 2000-07-06 |
WO2000038785A3 WO2000038785A3 (en) | 2000-09-21 |
Family
ID=26918579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/031039 WO2000038785A2 (en) | 1998-12-31 | 1999-12-29 | Methods for treating certain diseases using naaladase inhibitors |
Country Status (8)
Country | Link |
---|---|
US (2) | US6444657B1 (en) |
EP (2) | EP1371367A1 (en) |
JP (1) | JP2002533421A (en) |
AT (1) | ATE248592T1 (en) |
AU (1) | AU2392100A (en) |
CA (1) | CA2354052A1 (en) |
DE (1) | DE69911057D1 (en) |
WO (1) | WO2000038785A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070782B1 (en) * | 1992-11-05 | 2006-07-04 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US6953668B1 (en) | 1992-11-05 | 2005-10-11 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen |
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
CA2212846A1 (en) | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US20040253246A1 (en) * | 1996-02-23 | 2004-12-16 | Israeli Ron S. | Prostate-specific membrane antigen and uses thereof |
US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
ATE239741T1 (en) * | 1999-09-14 | 2003-05-15 | Meiji Seika Kaisha | PHOSPHONIC ACID DERIVATIVES FOR INHIBITING CARBOXYPEPTIDASE B |
WO2001092273A2 (en) * | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
JP2005507857A (en) * | 2001-02-07 | 2005-03-24 | ベズ イズレイル ディーコネス メディカル センター | Modified PSMA ligands and uses related thereto |
AU2002303856A1 (en) | 2001-05-24 | 2002-12-03 | Neuronz Limited | Gpe analogs and peptidomimetics |
US20070004641A1 (en) * | 2001-05-24 | 2007-01-04 | Neuren Pharmaceuticals Limited | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate |
US7605177B2 (en) * | 2001-05-24 | 2009-10-20 | Neuren Pharmaceuticals Limited | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration |
US7714020B2 (en) * | 2001-05-24 | 2010-05-11 | Neuren Pharmaceuticals Limited | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate |
US7148250B2 (en) * | 2001-12-28 | 2006-12-12 | Guilford Pharmaceuticals Inc. | Indoles as NAALADase inhibitors |
MXPA05009492A (en) * | 2003-03-03 | 2005-12-14 | Guilford Pharm Inc | Thiolactones. |
DE102008060549A1 (en) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug-peptide construct for extracellular accumulation |
WO2012108831A1 (en) * | 2011-02-11 | 2012-08-16 | Redeco Chem Ab | Metabotropic glutamate receptor group i antagonists for treatment of abnormal union of tissue |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048399A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Certain phosphinyl derivatives useful as naaladase inhibitors |
WO1997048409A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
WO1997048400A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Hydroxy-phosphinyl derivatives useful as naaladase inhibitors |
WO1998013046A1 (en) * | 1996-09-27 | 1998-04-02 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
WO1998045257A1 (en) * | 1997-04-09 | 1998-10-15 | Guilford Pharmaceuticals Inc. | Thio derivatives as naaladase inhibitors |
WO1998045256A1 (en) * | 1997-04-04 | 1998-10-15 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
WO1998047906A1 (en) * | 1997-04-24 | 1998-10-29 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
WO1998053812A1 (en) * | 1997-05-27 | 1998-12-03 | Guilford Pharmaceuticals Inc. | Inhibitors of naaladase enzyme activity |
WO1999008521A1 (en) * | 1997-08-14 | 1999-02-25 | Department Of The Army, U.S. Government | Treatment or prophylaxis of retinal pathology and spinal cord injury |
WO1999033849A1 (en) * | 1997-12-31 | 1999-07-08 | Guildford Pharmaceuticals Inc. | Prodrugs of naaladase inhibitors |
WO1999033847A1 (en) * | 1997-12-31 | 1999-07-08 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
WO1999050272A1 (en) * | 1998-03-30 | 1999-10-07 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
WO2000001668A2 (en) * | 1998-07-06 | 2000-01-13 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5162512A (en) | 1982-03-09 | 1992-11-10 | Cytogen Corporation | Amine derivatives of anthracycline antibodies |
US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4857637A (en) | 1986-05-07 | 1989-08-15 | Genentech, Inc. | Methods and compositions for immunologically modulating growth hormone receptor activity |
US5190976A (en) | 1986-07-10 | 1993-03-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US4906779A (en) | 1986-07-10 | 1990-03-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
US5093525A (en) | 1986-07-10 | 1992-03-03 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists |
CA1305177C (en) | 1987-06-30 | 1992-07-14 | Yasufumi Ohfune | Carboxycyclopropylglycine and process for producing the same |
US4918064A (en) | 1987-10-21 | 1990-04-17 | G. D. Searle & Co. | Phenyl glycines for use in reducing neurotoxic injury |
US5871472A (en) | 1987-11-17 | 1999-02-16 | Brown University Research Foundation | Planting devices for the focal release of neuroinhibitory compounds |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
EP1762623A1 (en) | 1988-01-22 | 2007-03-14 | ZymoGenetics, Inc. | Methods for producing biologically active peptide dimers |
US4937183A (en) | 1988-02-03 | 1990-06-26 | Cytogen Corporation | Method for the preparation of antibody-fragment conjugates |
US5047227A (en) | 1988-02-08 | 1991-09-10 | Cytogen Corporation | Novel and improved antibodies for site specific attachment of compounds |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
CA2002011A1 (en) | 1988-11-14 | 1990-05-14 | Anthony F. Purchio | Normal human growth regulatory receptor for tgf-beta |
US4994446A (en) | 1989-01-03 | 1991-02-19 | Ramot - University Authority For Applied Research And Industrial Development Ltd. | Drug system |
US5136080A (en) | 1989-12-04 | 1992-08-04 | Burroughs Wellcome Co. | Nitrile compounds |
US5262568A (en) | 1990-03-02 | 1993-11-16 | State Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5336689A (en) | 1990-03-02 | 1994-08-09 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
US5137877B1 (en) | 1990-05-14 | 1996-01-30 | Bristol Myers Squibb Co | Bifunctional linking compounds conjugates and methods for their production |
GB9106678D0 (en) | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
ATE196548T1 (en) | 1991-05-10 | 2000-10-15 | Genentech Inc | SELECTING AGONISTS AND ANTAGONISTS OF LIGANDS |
JP2632754B2 (en) | 1991-05-21 | 1997-07-23 | 塩野義製薬株式会社 | Brain glutamate release inhibitor |
US5229495A (en) | 1991-06-18 | 1993-07-20 | Ludwig Institute For Cancer Research | Substantially pure receptor like TGF-β 1 binding molecules and uses thereof |
US5216126A (en) | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
US5543143A (en) | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
WO1993019177A1 (en) | 1992-03-18 | 1993-09-30 | The General Hospital Corporation | FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY |
US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
US5668118A (en) * | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
US5489525A (en) | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
JPH08504763A (en) | 1992-10-29 | 1996-05-21 | セルトリックス ファーマシューティカルズ,インコーポレイテッド | Use of TGF-β receptor fragment as a therapeutic agent |
ATE342356T1 (en) | 1992-11-05 | 2006-11-15 | Sloan Kettering Inst Cancer | PROSTATE-SPECIFIC MEMBRANE ANTIGEN |
US5565439A (en) | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
US5614502A (en) * | 1993-01-15 | 1997-03-25 | The General Hospital Corporation | High-pressure impulse transient drug delivery for the treatment of proliferative diseases |
US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
US5449761A (en) | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
US5500420A (en) | 1993-12-20 | 1996-03-19 | Cornell Research Foundation, Inc. | Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia |
US5583153A (en) * | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
US5698402A (en) | 1995-02-23 | 1997-12-16 | Dianon Systems, Inc. | Methods for diagnosing benign prostatic hyperplasia |
CA2212846A1 (en) | 1995-02-24 | 1996-08-29 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US5616561A (en) | 1995-03-31 | 1997-04-01 | Regents Of The University Of California | TGF-β antagonists as mitigators of radiation-induced tissue damage |
US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US5830210A (en) | 1996-10-21 | 1998-11-03 | Plc Medical Systems, Inc. | Catheter navigation apparatus |
US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
US6028216A (en) | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
US6265609B1 (en) * | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
US6395718B1 (en) * | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6228888B1 (en) | 1999-07-01 | 2001-05-08 | Guilford Pharmaceuticals Inc. | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
-
1999
- 1999-10-22 US US09/425,197 patent/US6444657B1/en not_active Expired - Fee Related
- 1999-12-29 WO PCT/US1999/031039 patent/WO2000038785A2/en active IP Right Grant
- 1999-12-29 DE DE69911057T patent/DE69911057D1/en not_active Expired - Lifetime
- 1999-12-29 JP JP2000590733A patent/JP2002533421A/en active Pending
- 1999-12-29 EP EP03019536A patent/EP1371367A1/en not_active Withdrawn
- 1999-12-29 EP EP99967675A patent/EP1140048B1/en not_active Expired - Lifetime
- 1999-12-29 CA CA002354052A patent/CA2354052A1/en not_active Abandoned
- 1999-12-29 AT AT99967675T patent/ATE248592T1/en not_active IP Right Cessation
- 1999-12-29 AU AU23921/00A patent/AU2392100A/en not_active Abandoned
-
2002
- 2002-08-01 US US10/209,011 patent/US6806261B2/en not_active Expired - Fee Related
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048399A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Certain phosphinyl derivatives useful as naaladase inhibitors |
WO1997048409A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
WO1997048400A1 (en) * | 1996-06-17 | 1997-12-24 | Guilford Pharmaceuticals Inc. | Hydroxy-phosphinyl derivatives useful as naaladase inhibitors |
WO1998013046A1 (en) * | 1996-09-27 | 1998-04-02 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
WO1998045256A1 (en) * | 1997-04-04 | 1998-10-15 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
WO1998045257A1 (en) * | 1997-04-09 | 1998-10-15 | Guilford Pharmaceuticals Inc. | Thio derivatives as naaladase inhibitors |
WO1998047906A1 (en) * | 1997-04-24 | 1998-10-29 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
WO1998053812A1 (en) * | 1997-05-27 | 1998-12-03 | Guilford Pharmaceuticals Inc. | Inhibitors of naaladase enzyme activity |
WO1999008521A1 (en) * | 1997-08-14 | 1999-02-25 | Department Of The Army, U.S. Government | Treatment or prophylaxis of retinal pathology and spinal cord injury |
WO1999033849A1 (en) * | 1997-12-31 | 1999-07-08 | Guildford Pharmaceuticals Inc. | Prodrugs of naaladase inhibitors |
WO1999033847A1 (en) * | 1997-12-31 | 1999-07-08 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
WO1999050272A1 (en) * | 1998-03-30 | 1999-10-07 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
WO2000001668A2 (en) * | 1998-07-06 | 2000-01-13 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors useful as pharmaceutical compounds and compositions |
Non-Patent Citations (6)
Title |
---|
DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US SAMOILOVICH, E. O. ET AL: "The effectiveness of phosphonic acid derivatives and their combinations with interferon inducers in cell cultures and mice with herpes meningoencephalitis" retrieved from STN Database accession no. 111:224810 XP002139382 & VOPR. VIRUSOL. (1989), 34(4), 466-74 , * |
LU, X.-C. M. (1) ET AL: "Neuroprotective effect of NAALADase inhibition in rat MCAO is partially mediated through TGF -beta." SOCIETY FOR NEUROSCIENCE ABSTRACTS., (1999) VOL. 25, NO. 1-2, PP. 2231. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE. MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 SOCIETY FOR NEUROSCIENCE. , XP000913437 * |
SHAH, B. (1) ET AL: "NAALADase inhibition enhances myelination in dorsal root ganglia-Schwann cell co-cultures." SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 1561. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 , XP000913438 * |
THOMAS, AJIT G. (1) ET AL: "The role of TGF -beta in the neuroprotection mediated by NAALADase inhibition in cortical cell cultures." SOCIETY FOR NEUROSCIENCE ABSTRACTS., (1999) VOL. 25, NO. 1-2, PP. 2231. MEETING INFO.: 29TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE. MIAMI BEACH, FLORIDA, USA OCTOBER 23-28, 1999 SOCIETY FOR NEUROSCIENCE. , XP000913436 * |
YAO, Y.-M. (1) ET AL: "Inhibition of NAALADase activity promotes myelin formation following mouse sciatic nerve cryolesion." SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1997) VOL. 23, NO. 1-2, PP. 2302. MEETING INFO.: 27TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE NEW ORLEANS, LOUISIANA, USA OCTOBER 25-30, 1997 , XP000913439 * |
YAO, Y.-M. (1) ET AL: "NAALADase inhibition enhances myelination following sciatic nerve cryolesion and tellurium intoxication." SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 1755. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 2 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE. , XP000913440 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399461B2 (en) | 1993-11-05 | 2008-07-15 | Sloan-Kettering Institute For Cancer Research | Prostate-specific membrane antigen and uses thereof |
US8114965B2 (en) | 2001-10-23 | 2012-02-14 | Psma Development Company, Llc | Compositions of PSMA antibodies |
US8470330B2 (en) | 2001-10-23 | 2013-06-25 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
US9695248B2 (en) | 2001-10-23 | 2017-07-04 | Psma Development Company, Llc | PSMA antibodies and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2354052A1 (en) | 2000-07-06 |
JP2002533421A (en) | 2002-10-08 |
US6444657B1 (en) | 2002-09-03 |
EP1140048B1 (en) | 2003-09-03 |
US20030017965A1 (en) | 2003-01-23 |
EP1371367A1 (en) | 2003-12-17 |
US6806261B2 (en) | 2004-10-19 |
AU2392100A (en) | 2000-07-31 |
DE69911057D1 (en) | 2003-10-09 |
ATE248592T1 (en) | 2003-09-15 |
EP1140048A2 (en) | 2001-10-10 |
WO2000038785A3 (en) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6806261B2 (en) | Methods for treating certain diseases using naaladase inhibitors | |
RU2268881C2 (en) | Derivatives of pentadicarboxylic acid, pharmaceutical composition based on thereof and methods for treatment | |
AU2005237108A1 (en) | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | |
JP2010523682A (en) | Administration of carboline derivatives useful for the treatment of cancer and other diseases | |
TWI804743B (en) | Methods of treating idiopathic pulmonary fibrosis | |
JP4503836B2 (en) | NAALADase inhibitors useful as pharmaceutical compounds and compositions | |
JP4722288B2 (en) | AZA-heterocyclic compounds used to treat neurological injury and hair loss | |
KR20220098144A (en) | Alkyl esters of alpha-methyl-DL-tyrosine for use in treating cancer | |
TWI721697B (en) | Compounds used to treat osteoarthritis | |
MXPA01006753A (en) | Methods for treating certain diseases using naaladase inhibitors | |
JP2022521119A (en) | Inositol phosphate compounds for use in increasing tissue perfusion | |
AU2008248188A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
WO2023134732A1 (en) | Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids | |
JPS62198616A (en) | Agent for improving cerebral blood flow and protecting cerebral cell | |
EP4351574A1 (en) | Inhibitors of ttbk1 | |
AU2022288713A1 (en) | Inhibitors of ttbk1 | |
US20230248838A1 (en) | Central nervous system delivery of nonsteroidal anti-inflammatory drugs | |
WO2023174314A1 (en) | Use and treatment method of azetidine derivative | |
JPH04128225A (en) | Antitumor agent | |
RU2787757C2 (en) | Methods for use of pyruvate kinase activators | |
JP2006524186A (en) | Composition comprising diphenyl UraIMPDH inhibitor and apoptosis-inducing anticancer agent | |
JP2017066061A (en) | Therapeutic agent for alopecia areata | |
JPH10218766A (en) | Lacrimation-accelerating and keratoconjunctive disorder-treating agent | |
JPWO2006051757A1 (en) | Therapeutic or preventive agent for ischemic heart disease or ischemic cardiomyopathy | |
CZ20004471A3 (en) | AZA-heterocyclic compounds used for treating neurological disorders and loss of hair |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2354052 Country of ref document: CA Ref country code: CA Ref document number: 2354052 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 590733 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/006753 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999967675 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 23921/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999967675 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999967675 Country of ref document: EP |